Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Quantum Biopharma ( (TSE:QNTM) ) has issued an update.
Quantum BioPharma Ltd. announced the closing of the final $2.42 million tranche of a $5 million financing round on March 31, 2025. The funds will support the development of drug candidates and commercialization efforts, with a focus on advancing a new alcohol misuse treatment, rekvry™, for emergency and hospital settings. This financial boost is expected to sustain operations until at least the first quarter of 2027, potentially strengthening the company’s market position in the biopharmaceutical industry.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders. The company, through its subsidiary Lucid Psycheceuticals Inc., is advancing its lead compound Lucid-MS for multiple sclerosis and holds strategic investments through FSD Strategic Investments Inc.
YTD Price Performance: 109.80%
Average Trading Volume: 2,880,577
Technical Sentiment Signal: Buy
Current Market Cap: $16.32M
For detailed information about QNTM stock, go to TipRanks’ Stock Analysis page.